5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine

Identification

Generic Name
5-[(4-Methylphenyl)Sulfanyl]-2,4-Quinazolinediamine
DrugBank Accession Number
DB04306
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 282.363
Monoisotopic: 282.093917158
Chemical Formula
C15H14N4S
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UDihydrofolate reductase, mitochondrialNot AvailableHumans
UDihydrofolate reductaseNot AvailableYeast
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazanaphthalenes
Sub Class
Benzodiazines
Direct Parent
Quinazolinamines
Alternative Parents
Diarylthioethers / Thiophenol ethers / Toluenes / Aminopyrimidines and derivatives / Imidolactams / Heteroaromatic compounds / Sulfenyl compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds
show 1 more
Substituents
Amine / Aminopyrimidine / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Benzenoid / Diarylthioether / Heteroaromatic compound / Hydrocarbon derivative / Imidolactam
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
UOJFGEAPSYQDIP-UHFFFAOYSA-N
InChI
InChI=1S/C15H14N4S/c1-9-5-7-10(8-6-9)20-12-4-2-3-11-13(12)14(16)19-15(17)18-11/h2-8H,1H3,(H4,16,17,18,19)
IUPAC Name
5-[(4-methylphenyl)sulfanyl]quinazoline-2,4-diamine
SMILES
CC1=CC=C(SC2=CC=CC3=C2C(N)=NC(N)=N3)C=C1

References

General References
Not Available
PubChem Compound
446245
PubChem Substance
46504871
ChemSpider
393654
BindingDB
18046
ChEMBL
CHEMBL83547
ZINC
ZINC000000172633
PDBe Ligand
TQ4
PDB Entries
1ia2

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP2.94ALOGPS
logP3.74Chemaxon
logS-4.4ALOGPS
pKa (Strongest Acidic)16.67Chemaxon
pKa (Strongest Basic)6.59Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area77.82 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity86.19 m3·mol-1Chemaxon
Polarizability30.17 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9948
Blood Brain Barrier+0.9254
Caco-2 permeable+0.5613
P-glycoprotein substrateNon-substrate0.6828
P-glycoprotein inhibitor INon-inhibitor0.8931
P-glycoprotein inhibitor IINon-inhibitor0.8293
Renal organic cation transporterNon-inhibitor0.8211
CYP450 2C9 substrateNon-substrate0.8058
CYP450 2D6 substrateNon-substrate0.8284
CYP450 3A4 substrateNon-substrate0.7663
CYP450 1A2 substrateInhibitor0.9511
CYP450 2C9 inhibitorNon-inhibitor0.7469
CYP450 2D6 inhibitorNon-inhibitor0.9286
CYP450 2C19 inhibitorInhibitor0.5371
CYP450 3A4 inhibitorNon-inhibitor0.8465
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5596
Ames testNon AMES toxic0.6413
CarcinogenicityNon-carcinogens0.9263
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.1551 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9786
hERG inhibition (predictor II)Non-inhibitor0.7843
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0006-1390000000-8f46b4548e1338989189
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-0090000000-bddd031037e3f3942675
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0090000000-ad9c97ce59ed70876e1a
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-1090000000-579e667f2b3e01c11159
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0090000000-e946d9bac0eb76bff7c8
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01di-4290000000-58a9dc53b07fafbda40d
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-06du-4930000000-83696cf45974efd7018d
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-172.5665496
predicted
DarkChem Lite v0.1.0
[M-H]-165.43922
predicted
DeepCCS 1.0 (2019)
[M+H]+172.9175496
predicted
DarkChem Lite v0.1.0
[M+H]+167.79721
predicted
DeepCCS 1.0 (2019)
[M+Na]+172.5890496
predicted
DarkChem Lite v0.1.0
[M+Na]+173.89037
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Nadp binding
Specific Function
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Required to prevent uracil accumulation in mtDNA. Binds its own mRNA and that of DHFR.
Gene Name
DHFRL1
Uniprot ID
Q86XF0
Uniprot Name
Dihydrofolate reductase, mitochondrial
Molecular Weight
21619.88 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Kind
Protein
Organism
Yeast
Pharmacological action
Unknown
General Function
Nadp binding
Specific Function
Key enzyme in folate metabolism. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis.
Gene Name
DFR1
Uniprot ID
P22906
Uniprot Name
Dihydrofolate reductase
Molecular Weight
22138.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52